China Resources Double-Crane PharmaceuticalLtd Full Year 2024 Earnings: Misses Expectations

China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥11.2b (up 9.7% from FY 2023).
• Net income: CN¥1.63b (up 22% from FY 2023).
• Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: CN¥1.58 (up from CN¥1.30 in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Resources Double-Crane PharmaceuticalLtd Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 5.2%.

Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 3.1% from a week ago.

Valuation

China Resources Double-Crane PharmaceuticalLtd's financial results now indicate the company's shares could present an opportunity based on 6 important indicators. You can access our in-depth analysis and discover what the outlook is like for the stock by clicking here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.